Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination
Journal of the American Medical Directors Association · 2026-07 · 27 (7) · 106214
DOI: 10.1016/j.jamda.2026.106214 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of the American Medical Directors Association, 2026-07. Verfasst von Stefan Gravenstein und 9 weiteren Autor:innen. Beteiligte Einrichtung: Warren Alpert Medical School, Brown University, Providence, RI, USA; Department of Health Services, Policy & Practice, School of Public Health, Brown…. Hauptthemen laut MEDLINE: Nursing Home Residents, COVID-19, COVID-19 Vaccines, Vaccination. Die Arbeit nennt 15 Literaturangaben. Gefördert von: Health Services Research and Development, US Department of Veterans Affairs.
Themen: Langzeitpflege
Abstract (Originalsprache)
OBJECTIVES Nursing home residents received updated monovalent SARS-CoV-2 vaccines to protect them from the most recently emerging SARS-CoV-2 variants. We evaluated nursing home residents for the extent and durability of protection from hospitalization or death after monovalent KP.2 vaccination. DESIGN Retrospective cohort study using a target trial emulation design. We conducted a sequential, daily comparison of those who did and did not receive a KP.2 vaccination during the study period. Residents who received KP.2 were matched to unvaccinated residents based on index date and propensity scores incorporating demographics, vaccination status, and basic clinical characteristics. SETTING AND PARTICIPANTS Long-stay residents living in Veterans Affairs nursing homes between September 18, 2024, and October 30, 2024. METHODS The primary exposure was KP.2 vaccination vs no SARS-CoV-2 vaccine during the study period. The primary outcome was a test-confirmed SARS-CoV-2 infection. Secondary outcome was composite outcome of COVID-19-associated hospitalizations within 21 days or death within 30 days of confirmed infection. RESULTS Among eligible residents, a matched cohort of 1711 paired person trials were created (average age 76, 95% male, 28% African American). Vaccine effectiveness against COVID-19 infection was 38% at week 12 (95% CI, 13%-56%) and 4% at week 18 (95% CI, -30 to 29%). Vaccine effectiveness against hospitalization or death was 77% at week 12 (95% CI, 60%-90%) and 53% at week 18 (95% CI, 21%-71%). CONCLUSION AND IMPLICATIONS Vaccination with the KP.2 updated SARS-CoV-2 vaccine provided significant clinical protection against hospitalization or death among nursing home residents. This protection started to wane within a few months of vaccination, mirroring antibody decline reported in other studies. Our findings support consideration of twice-annual vaccination strategy to optimize protection in this vulnerable population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Warren Alpert Medical School, Brown University, Providence, RI, USA; Department of Health Services, Policy & Practice, School of Public Health, Brown University, Providence, RI, USA; Transformative Health Systems Resear…
- Transformative Health Systems Research to Improve Veteran Equity and Independence Center of Innovation (THRIVE COIN), Veterans Affairs Providence Health Care System, Providence, RI, USA.
- Warren Alpert Medical School, Brown University, Providence, RI, USA; Transformative Health Systems Research to Improve Veteran Equity and Independence Center of Innovation (THRIVE COIN), Veterans Affairs Providence Heal…
- Division of Geriatrics and Palliative Medicine, Rhode Island Hospital, Providence, RI, USA.
- Case Western Reserve University School of Medicine, Cleveland, OH, USA; Geriatric Research Education and Clinical Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA.
- Department of Health Services, Policy & Practice, School of Public Health, Brown University, Providence, RI, USA; Transformative Health Systems Research to Improve Veteran Equity and Independence Center of Innovation (T…
Förderung
- Health Services Research and Development
- US Department of Veterans Affairs
Zitieren
APA
Gravenstein, S., DeVone, F., Abul, Y., Halladay, C. W., Rudolph, J. L., Nugent, C., Skov, B., Yavuz, S., Canaday, D. H., & McConeghy, K. W. (2026). Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination. Journal of the American Medical Directors Association, 27(7), 106214. https://doi.org/10.1016/j.jamda.2026.106214
Vancouver
Gravenstein S, DeVone F, Abul Y, Halladay CW, Rudolph JL, Nugent C, et al. Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination. Journal of the American Medical Directors Association. 2026;27(7):106214. doi:10.1016/j.jamda.2026.106214
BibTeX
@article{Gravenstein2026,
author = {Gravenstein, Stefan and DeVone, Frank and Abul, Yasin and Halladay, Christopher W and Rudolph, James L and Nugent, Clare and Skov, Benjamin and Yavuz, Selma and Canaday, David H and McConeghy, Kevin W},
title = {Durability of Clinical Protection in Nursing Home Residents Following Monovalent KP.2 SARS-CoV-2 Vaccination},
journal = {Journal of the American Medical Directors Association},
year = {2026},
volume = {27},
number = {7},
pages = {106214},
doi = {10.1016/j.jamda.2026.106214}
}
EUVIMED